SecBot SecBot
DEFA14A ·Filed Jun 8, 2026

ANIK

Anika Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago SEC0001140361-26-024374
Proxy solicitation materials
Actionable Insight • Neutral

Monitor ISS and Glass Lewis updated recommendations following this second supplement; a favorable revision could increase passage probability for Proposal 4, removing a small overhang. If the revised plan passes, the dilution impact is lower than originally feared, but the routine nature of this supplement suggests limited near-term price impact.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.60
T+0 close · Jun 8, 2026 · via day close
Latest settled
+44.59%
T+60 · $21.11
Vs SPY
+41.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $14.60entry
  2. T+1 · 5mo ago −0.21%α +0.09% · $14.57
  3. T+5 · 5mo ago +0.07%α −2.04% · $14.61
  4. T+20 · 4mo ago +9.79%α +8.16% · $16.03
  5. T+60 · 3mo ago +44.59%α +41.54% · $21.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Anika Therapeutics filed a second supplement to its proxy statement responding to ISS's unfavorable recommendation on Proposal 4 (equity incentive plan amendment). The board reduced the requested new share increase from 475,000 to 350,000 shares, lowering estimated dilution from ~29.40% to ~24.88%, and is now seeking approval of a 'Revised Seventh Amended Plan' capping total authorized shares at 6,110,000. The matter will be voted on at the June 18, 2026 annual meeting.

Key Financial Metrics

Meeting
2026-06-18

Key Facts

  • Board cut requested new shares from 475,000 to 350,000 after ISS flagged excessive dilution (estimated 29.40% fully diluted)
  • Revised plan would increase total shares reserved from 5,760,000 to 6,110,000, reducing estimated dilution to ~24.88%
  • Company noted ~$3.0 million in annualized savings from recent restructuring actions to support disciplined equity usage
  • Three-year average burn rate is 3.92% per fiscal years 2023-2025
  • Annual meeting scheduled for June 18, 2026; board unanimously recommends voting FOR the revised plan

Financial Impact

Proposed dilution reduced from ~29.4% to ~24.88% by cutting share request by 125,000 shares (26% reduction). No dollar figures for compensation or dilution impact provided.

dilutionequity compensation reserve

Risk Factors

  • Plan may still fail if ISS recommendation remains unfavorable despite the concession
  • Dilution of ~24.88% is still relatively high and could weigh on the stock over time
  • Engagement with proxy advisory firms could continue to pressure management on equity usage

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-024374
Document: 0001140361-26-024374-index-headers.html0001140361-26-024374
Document: 0001140361-26-024374-index.html0001140361-26-024374
Document: 0001140361-26-024374.txt0001140361-26-024374

Track record

13 reports on ANIK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
  2. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
  3. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
  4. Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
  7. Jun 8, 202623w ago DEFA14A Neutral 4/10 Viewing Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
  8. Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
  9. Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
  10. Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 5h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026